Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 84.6%

Neg 0% Neu 0% Pos 84.6%

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $111 to $115.